8-K: UroGen Pharma Presents Pipeline Progress at TD Cowen Healthcare Conference

UroGen Pharma highlighted the potential of its pipeline, including JELMYTO, UGN-102, and UGN-301, at the TD Cowen 44th Annual Health Care Conference.

Summary

• UroGen Pharma is focused on developing treatments for urothelial cancers using its proprietary RTGel technology.
• JELMYTO is the first and only FDA-approved non-surgical treatment for low-grade upper tract urothelial cancer (LG-UTUC).
• UGN-102 is being developed as a non-surgical option for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with a planned NDA submission in 2024.
• UGN-301 is an anti-CTLA4 monoclonal antibody being evaluated for high-grade non-muscle invasive bladder cancer (HG-NMIBC) as a monotherapy and in combination with other agents.
• The company has a strong balance sheet with $154 million in cash as of September 30, 2023.
• JELMYTO's revenue is showing long-term growth, with $86 million in full-year 2023 revenue.
• The addressable U.S. patient populations for JELMYTO, UGN-102, and UGN-301 are estimated to be approximately 6,000-7,000, 82,000, and 18,700, respectively.
• The market opportunities for these treatments are estimated to be $700 million, $3 billion, and $2 billion, respectively.
• Clinical trial data for UGN-102 from the ATLAS and ENVISION trials show promising results with a 79% complete response rate in the ENVISION trial.
• UroGen is also developing UGN-103, a next-generation mitomycin-based formulation, with a planned Phase 3 study in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, revenue growth, and a solid financial position. The company is making significant progress in its pipeline and has a clear strategy for future growth. However, there are inherent risks in drug development and commercialization.

Positives

• JELMYTO has demonstrated a 58% complete response rate at 3 months and 82% durability of response at 12 months in the OLYMPUS Phase 3 trial.
• Real-world evidence supports JELMYTO's efficacy and safety.
• UGN-102 has shown a 79% complete response rate in the ENVISION trial.
• UGN-102 has a 55% risk reduction for recurrence, progression, or death compared to TURBT alone in the ATLAS trial.
• UroGen has a strong balance sheet with $154 million in cash.
• The company has a growing prescriber base for JELMYTO.
• The 2022 label update for JELMYTO extended the stability period of the admixture to 96 hours, increasing operational efficiencies.
• UroGen has a licensing agreement with medac GmbH for UGN-103, a next-generation mitomycin-based formulation, with potential IP protection until 2041.

Negatives

• Urothelial cancers are challenging to treat, often requiring repetitive surgeries.
• There is a risk of complications associated with product development and commercialization activities.
• The market acceptance of UroGen's products may vary compared to alternative therapies.
• The company's patent applications may not be successful, limiting intellectual property protection.
• The company is reliant on the success of its clinical trials and regulatory approvals.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Risks

• Clinical trials may not be successful, and there may be safety or other complications.
• Results from prior trials may not be indicative of future results.
• There may be unforeseen delays in progressing clinical trials and reporting data.
• Prescriber behavior may change based on new data or labeling limitations.
• Regulatory approval may not be obtained within the expected timeframe or at all.
• The company may face challenges in maintaining regulatory approval.
• The RTGel technology may not perform as expected.
• UroGen may not be able to attract or retain key management and personnel.

Future Outlook

UroGen plans to submit an NDA for UGN-102 in 2024, advance pre-commercial activities for UGN-102, accelerate JELMYTO adoption, and advance its immuno-oncology pipeline, focusing on UGN-301. The company also plans to initiate a Phase 3 study for UGN-103 in 2024.

Management Comments

• UroGen is pioneering new therapies to meet the unique needs of patients with urothelial cancers.
• The company is confident in the future of JELMYTO.
• UGN-102 is anticipated to be a primary driver of UroGen's future growth.
• UroGen is focused on maximizing shareholder value through disciplined investment.

Industry Context

UroGen is addressing unmet needs in urothelial cancer treatment by developing non-surgical options, which aligns with a broader trend towards less invasive procedures and personalized medicine in oncology. The company is competing with traditional treatments like TURBT and BCG, as well as other companies developing novel therapies for bladder cancer.

Comparison to Industry Standards

• The 79% complete response rate for UGN-102 in the ENVISION trial is competitive with other investigational therapies for LG-IR-NMIBC.
• The 55% risk reduction for recurrence, progression, or death in the ATLAS trial for UGN-102 is a significant improvement over TURBT alone, which is a standard treatment.
• JELMYTO's 58% complete response rate at 3 months and 82% durability of response at 12 months in the OLYMPUS trial are favorable compared to historical outcomes with traditional treatments for LG-UTUC.
• The development of UGN-301 as an anti-CTLA4 antibody aligns with the growing interest in immunotherapy for bladder cancer, similar to companies like Bristol Myers Squibb and Merck who have developed checkpoint inhibitors for other cancers.
• The use of RTGel technology is a unique approach to drug delivery, differentiating UroGen from companies using traditional methods of drug administration.

Stakeholder Impact

• Shareholders may benefit from the potential for increased revenue and market value.
• Patients may benefit from new, less invasive treatment options for urothelial cancers.
• Employees may benefit from the company's growth and success.
• Urologists may benefit from new treatment options for their patients.

Next Steps

• UroGen plans to submit an NDA for UGN-102 to the FDA in 2024.
• The company will advance pre-commercial activities for UGN-102.
• UroGen will accelerate JELMYTO adoption using an adjusted sales strategy.
• The company will focus on UGN-301 as monotherapy and combination therapy to advance its immuno-oncology pipeline.
• UroGen plans to initiate a Phase 3 study for UGN-103 in 2024.

Key Dates

Keywords

UroGen Pharma, JELMYTO, UGN-102, UGN-301, RTGel, urothelial cancer, LG-UTUC, LG-IR-NMIBC, HG-NMIBC, chemoablation, immunotherapy, clinical trials, FDA approval